Skip to main content
OpenTrials
Completed

NCT Number: NCT02762721

Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples

The primary objective of this study is to estimate the frequency of FGFR2 fusions in archived intrahepatic cholangiocarcinoma (iCCA) or mixed hepatocellular-cholangiocarcinoma (HCC-CCA) tumor samples

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Rozzano, MI, Italy

Loading trial locations.

About this study

This is a non-interventional, observational study of archived human tissue samples; no surgical procedures will be required and no treatment will be provided as part of this study. Approximately 150 archived tissue samples obtained from patients with iCCA or mixed HCC-CCA will be analyzed for somatic alteration status and will include cholangiocarcinoma-specific FGFR2 fusion isoforms.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • If required by law or local regulations (i.e., the sample is from an identifiable subject), signed written informed consent should be granted prior to use of the sample in the study
  • ≥ 18 years of age
  • Histologically or cytologically confirmed iCCA or mixed HCC-CCA, who are/were eligible for systemic therapy (samples collected prior to initiation of the systemic therapy may be submitted for testing)
  • Have one or more formalin fixed and paraffin embedded blocks available. If blocks are not evaluable, 7-10 unstained, non-baked slides with 5-micron thick sections with at least 20% tumor tissue should be available. (Potential participants who are scheduled to undergo surgical treatment may agree to provide surplus of tissues not required for diagnosis and have to provide informed consent prior to the surgery.)

Exclusion criteria

  • Not applicable: Patients must meet all of the inclusion criteria.

Treatment and study plan

Primary outcomes

  1. Estimate the frequency of FGFR2 fusions in archived iCCA or mixed HCC-CCA tumor tissue samples

    Time frame: Archived tumor samples will be collected through study completion, up to 18 months

    Archived tumor samples will be collected and analyzed using a Next Generation Sequencing panel.

Secondary outcomes

  1. Determine the frequency of potential actionable mutations or genetic alterations in iCCA or mixed HCC-CCA

    Time frame: Archived tumor samples will be collected through study completion, up to 18 months

    Archived tumor samples will be collected and analyzed using a Next Generation Sequencing panel.

  2. Formulate genetic screening recommendations for newly diagnosed patients with iCCA or mixed HCC-CCA

    Time frame: Archived tumor samples will be collected through study completion, up to 18 months

    Archived tumor samples will be collected and analyzed using a Next Generation Sequencing panel.

Sponsors and collaborators

Lead sponsor

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Industry

Registry information

Official study title

Molecular Analysis of Oncogenes in Tumor Samples From Adult Patients With Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
May 5, 2016
Registry last updated
Jun 8, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.